

CURRICULUM VITAE

Date: July 28, 2017

PERSONAL INFORMATION

Name: Richard P. Morrison, Ph.D.
Citizenship: U.S.
Foreign Languages: None
Home Address: 102 Buckland PL
Little Rock, AR 72223
Work E mail: rpmorrison@uams.edu
Work Phone: 501-686-8599
Title: Executive Associate Dean for Research
Professor, Microbiology and Immunology
Department: Department of Microbiology and Immunology
Business Address: University of Arkansas for Medical Sciences
Department of Microbiology and Immunology
4301 West Markham St., Slot 511
Little Rock, AR 72205-7199

PROFESSIONAL CONSULTANTSHIPS:

Glaxo-Smith-Kline; 2003-2004
BT-PHARM; 2001-2003
CellTech; 1980-1982
Novartis 2007

EDUCATION

University of Oklahoma, Norman, Oklahoma	Ph.D.	1982
Montana State University, Bozeman, Montana	M.S.	1978
Montana State University, Bozeman, Montana	B.S.	1976

MILITARY SERVICE: None

BOARD CERTIFICATION:

1981-present ASCP Microbiologist

POSTDOCTORAL TRAINING

- 1986-1988 Special Volunteer, NIH, NIAID, Laboratory of Microbial Structure and Function, Rocky Mountain Laboratories, Hamilton, Montana
- 1982-1986 Staff Fellow, NIH, NIAID, Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, Montana

ACADEMIC APPOINTMENTS (In reverse chronological order)

- 2017-present Executive Associate Dean for Research, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
- 2007-present Professor, Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas (Tenure Awarded 2007)
- 2007-2017 Professor and Chair, Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas (Tenure Awarded 2007)
- 2007-2012 Endowed Chair in Sciences Basic to Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Rotating Endowed Chair. Inaugural holder.
- 2004-2007 Professor, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama (Tenure Awarded 2004)
- 2002-2004 Professor, Department of Microbiology, Montana State University, Bozeman, Montana
- 1998-2004 Affiliate Associate Professor, Department of Pathology, University of Washington School of Medicine, Seattle, WA
- 1997-2002 Associate Professor, Department of Microbiology, Montana State University, Bozeman, Montana (Tenure Awarded 2000)
- 1994-1997 Associate Professor, Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama
- 1991-1994 Microbiologist, NIH, NIAID, Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, Hamilton, Montana
- 1990-1994 Faculty Affiliate, Division of Biological Sciences (Microbiology), University of Montana, Missoula, Montana
- 1990-1991 Senior Staff Fellow, NIH, NIAID, Laboratory of Intracellular Parasites, Rocky Mountain Laboratories, Hamilton, Montana
- 1988-1990 Senior Staff Fellow, NIH, NIAID, Laboratory of Microbial Structure and Function, Rocky Mountain Laboratories, Hamilton, Montana

AWARDS/HONORS

- 2007-2012 Endowed Chair in Sciences Basic to Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
- 2001 Recipient of the Charles and Nora L. Wiley Faculty Award for Meritorious Research, Montana State University
- 1994 Elected ; Fellow, American Academy of Microbiology
- 1992 NIH Intramural Award of Merit; “For highly creative and innovative research achievements in NIAID research on the molecular biology and immunity of chlamydiae”.

PROFESSIONAL SOCIETIES

MEMBERSHIPS:

- 1976 – present American Society for Microbiology (ASM)
1981 – present American Society of Clinical Pathologists (ASCP)
1994 – present American Academy of Microbiology (AAM)
2003 – present Chlamydia Basic Research Society (CBRS)
2003 – present American Association of Immunologists (AAI)

ELECTED NATIONAL SOCIETY POSITIONS:

- 1998 – 2000 Councilor, Division of General Medical Microbiology, American Society for Microbiology
- 1996 – 1998 Alternate Councilor, Division of General Medical Microbiology, American Society of Microbiology.
- 1994 – 1995 Chairman, Division of General Medical Microbiology, American Society for Microbiology
- 1993 – 1994 Chair-Elect, Division of General Medical Microbiology American Society for Microbiology

COUNCILS AND COMMITTEES:

GRANT REVIEW BOARD: Chartered Member

- 2006 – 2009 Chartered Member, NIAID Host Interactions Bacterial Pathogens Study Section (HIBP)
- 2001 – 2005 Chairperson, American Heart Association, Immunology and Microbiology 2 Study Group

- 2001 – 2001 Member, American Heart Association, Consortia Great America 4A Peer Review Committee
- 1996 – 2000 Member, American Heart Association, Immunology and Microbiology Study Section 1

GRANT/PROGRAM REVIEW BOARDS: Ad hoc

Recent:

- NIH, National Center on Minority Health and Disparities. Exploratory Centers of Excellence (P20) 8/2009
- NIH, NIAID, Immune Defense Mechanisms at the Mucosa. Cooperative Study Group (U01) 3/2011
- NIH, NIAID, Strategies for the Protection of Pregnant Women and Infants against Infectious Diseases (R01) 1/2012
- San Antonio Vaccine Center Grants. 6/2012
- NIAID, Special Emphasis Panel 3/2013
- NIAID, Centers of Excellence for Translational Research 8/2013
- NIAID, Allergy, Immunology, Transplantation Research Committee, Ruth L. Kirschstein NRSA IRTG (T32) 2/2014
- NIAID, Support for Conferences and Scientific Meetings R13/U13 6/2016
- NIAID, Centers of Biomedical Research Excellence (COBRE) Phase I (P20) Review, 7/2016
- Atlantic Coast STI-CRC (U19) External Scientific Review Board. 4/2017
- NIAID, Infectious, Reproductive, Asthma and Pulmonary Conditions (IRAP) Study Section, 6/2017

Past:

- NIH Cancer Etiology Study Section (CE)
- NIH, National Center on Minority Health and Health Disparities Study Section
- NIAID Host Interactions Bacterial Pathogens Study Section (HIBP)
- NIAID Bacteriology and Mycology Study Section 1
- NIAID Bacteriology and Mycology Study Section 2
- NIAID Biological Sciences Study Section 1
- NIAID Tropical Medicine and Parasitology Study Section
- NIH National Center for Research Resources
- Edna McConnell Clark Foundation
- Merit Review Board, Department of Veterans Affairs
- Wellcome Trust, London, England
- Swiss National Science Foundation
- Natural Sciences and Engineering Research Council of Canada, Ottawa, Canada

Council:

- 1999 – 2002 Raymond W. Sarber Award Selection Committee, American Academy of Microbiology
- 2008 – 2012 Raymond W. Sarber Award Selection Committee, American Academy of Microbiology

UNIVERSITY ACTIVITIES:

2016 – present UAMS, Member, College of Medicine Faculty Compensation Committee
2016 – present UAMS, Member, Medical Student Admissions Committee
2013 – present UAMS Dean’s Executive Committee, member
2011 – 2014 UAMS, Dean’s Distinguished Lecture Committee, Chair
2010 – 2011 UAMS, Pathology Department Chair Search Committee, member
2010 UAMS Chancellor’s Research Retreat
2009 – present UAMS, DLAM Advisory Committee, Chair
2009 – present UAMS, BSL-3 Safety Committee, member
2009 – 2012 UAMS, Dean’s Executive Committee, member
2009 UAMS, Biochemistry Chair Search Committee, member
2009 – 2011 UAMS, Dean’s Distinguished Lecture Committee, member
2008 – 2010 UAMS IRB; Committee Member
2008 – 2010 Selection Committee; UAMS COM Faculty Teaching Awards Committee
2008 UAMS Chancellor’s Cabinet Strategic Planning Retreat, Feb. 28-29, 2008
2007 – 2017 UAMS, Director, Sequencing Core Facility
2007 – 2017 UAMS, Director, Flow Cytometry Core Facility
2007 – present Basic Sciences Chairs Committee, UAMS (Chair 2009-2010; 2016-2017)
2007 – present Council of Department Chairs, UAMS (Chair 2010-2011)
2007 – 2009 Biomedical Building Facilities Committee, UAMS
2005 – 2007 Department of Medicine Research and Development Group, Member, UAB
2004 – 2007 Gene Therapy Panel Alabama Vaccine Research Clinic, Member, UAB
2001 – 2004 Institutional Animal Care and Use Committee, Member, MSU
2002 – 2002 Faculty Search Committee, Chairperson, Department of Microbiology, MSU
2001 – 2004 Faculty Advisory Committee (FAC); VP Research and Creative Activities, MSU
2001 – 2002 Promotion and Tenure Committee; Dept. Microbiology, MSU
1999 – 2000 Undergraduate Curriculum Committee; Dept. Microbiology, MSU
1990 – 1994 Biosafety Committee, NIAID, RML
1990 – 1994 Animal Care and Use Committee, NIAID, RML

EDITORSHIPS

2016 – present *Journal of Infectious Diseases*, Editorial Advisory Board
2014 – present *The Journal of Immunology*, Associate Editor
2006 – 2015 *Infection and Immunity*; Editor.

EDITORIAL REVIEW BOARD: Member

2000 – 2006 *Infection and Immunity*
2005 – 2014 *Clinical and Vaccine Immunology* (formerly; *Clinical and Diagnostic Laboratory Immunology*)

EDITORIAL REVIEW BOARDS: Ad hoc

- *Journal of Immunology*
- *Journal of Infectious Diseases*
- *Journal of Clinical Investigation*
- *Proceedings of the National Academy of Sciences USA*
- *PlosOne*

- *Sexually Transmitted Diseases*
- *Microbial Pathogenesis*
- *Medical Microbiology and Immunology*
- *The Journal of Rheumatology*
- *Molecular Medicine Today*
- *Vaccine*
- *Archives of Medical Research*
- *Clinical and Diagnostic Laboratory Immunology*
- *Immunology*
- *Journal of Clinical Microbiology*
- *Clinical and Vaccine Immunology*

PRIMARY RESEARCH INTERESTS: My research program focuses on the pathogenesis of genital and respiratory chlamydial infections. The goals of these projects are to discover and define the elements of the host immune response that contribute to protective immunity, and which chlamydial antigens are the targets of those protective responses.

TEACHING EXPERIENCE:

Montana State University (courses taught):

- 1997 – 2003 General Pathology (undergraduate course; Dept. Microbiology)
- 1998 – 2004 Cell and Tissue Response to Injury (medical student course; WWAMI)
- 1999 Immunology Lab (undergraduate course; Dept. Microbiology)
- 1999 Departmental Seminar (Dept. Microbiology)
- 1999 Microbial Pathogenesis (graduate student course; Dept. Microbiology)
- 2000 – 2002 Seminar in Microbiology (undergraduate course; Dept. Microbiology)

University of Alabama at Birmingham:

- 1994 – 1997 Lecturer: Medical Microbiology; Dental students
- 1994 – 1997 Lecturer: Microbial Pathogenesis; graduate students
- 1994 – 1997 Section Leader: Infectious disease laboratory course; sophomore medical students
- 2004 – 2006 Lecturer: STD Pathogens lecture; sophomore medical students
- 2004 Section Leader; Infectious disease laboratory course; sophomore medical students
- 2005 Co-Director, Sophomore Medical Student Microbiology Laboratory
- 2006 Co-Director, Sophomore Medical Student Microbiology Laboratory

University of Arkansas for Medical Sciences

- 2007 – present Lecturer; Medical Microbiology, Immunology and Parasitology; Sophomore Medical Students
- 2008 – present Lecturer; Principles of Microbiology; graduate students.
- 2008 – 2012 Course Director; Graduate Journal Club
- 2011 – present Lecturer; Advanced Immunology; graduate students
- 2011 – present Lecturer; Advanced Microbial Pathogenesis; graduate students

TRAINEES

Trainee Name	Status (Pre or Post)	Degree at Entry	Training Period	Research Topic	Current Position
Elizabeth Naglak	Pre	BS	2012-2017	Chlamydia immunology	Assistant Professor-Jamestown Univ.
Jamal Stie, PhD	Post	PhD	2012-2014	Chlamydia immunology	Postdoctoral Fellow
Allister Loughran*	Pre	BS	2011-2016	Staphylococcus virulence	Postdoc
Joseph Graham*	Pre	BS	2010-2015	Coxiella Macrophage interactions	Postdoc
Kerry Evans *	Pre	BS	2010-2016	E coli cell wall	Grant Editor
Laura Broederdorf *	Pre	BS	2009-2012	<i>Coxiella</i> pathogenesis	Faculty Member; Hendrix College
Christina Farris	Pre	BS	2006-2010	Chlamydia immunology	PhD Staff Scientist US Navy
Brandon Fontenelle *	Pre	BS	2006-2011	T cell anergy	Postdoc
Daniel Prantner *	Pre	BS	2005-2010	Chlamydia: innate immunity	Postdoc
Sarah Cullen *	Pre	BS	2004-2009	Aging: Cell Biology	Postdoc
Stefania Cane *	Pre	BS	2004-2010	Aging: Cell Biology	Postdoc
Lakshimiprasad Potluri *	Pre	BS	2006-2011	E coli Cell wall biology	Postdoc
Lara Mrak *	Pre	BS	2008-present	Staphylococcus biofilms	MD/PhD Student
Paul Smith	Undergrad	N/A	2005	Humoral immunity in chlamydial infection	Undergrad, Univ. Oklahoma
Brittany Barclay	Undergrad	N/A	2003	<i>C. pneumoniae</i> antibody responses	Undergrad, Montana State University
Lisa Ablin	Undergrad	N/A	2003	<i>C. trachomatis</i> humoral immunity	BS, Dental School, Univ of Minnesota
Chris Anderson	Undergrad	N/A	2000-2001	<i>C. trachomatis</i> humoral immunity	BS, Dental School
Cindy Mortensen	Undergrad	N/A	2000-2001	<i>C. pneumoniae</i> pathogenesis	BS, research technician
Jason Rogers	Undergrad	N/A	1998	Humoral response to <i>C. trachomatis</i>	BS, scientist, Industry
Stefanie Lange	Undergrad	N/A	1998-1999	<i>C. trachomatis</i> acute inflammation	MD, Private Practice
Michael Jasumbach	Undergrad	N/A	1988-89	<i>C. trachomatis</i> hsp 60	MD, Private Practice

Tommy Day	Pre	BS	1998-2000	<i>C. pneumoniae</i> respiratory disease	MD, Private Practice
Wandy Beatty	Pre	BS	1990-1994	<i>C. trachomatis</i> persistence	PhD, faculty, Univ. of Washington
Ying Yuan	Pre	BS	1990-1993	<i>Chlamydia trachomatis</i> hsp 60	PhD, scientist, Industry

* Committee member only

MAJOR LECTURES AND VISITING PROFESSORSHIPS

"Immunology and Pathogenesis", The Edna McConnell Clark Foundation Workshop on Trachoma, Woods Hole, Massachusetts, 1987

"Animal Models and Antigen Production", The Edna McConnell Clark Foundation Workshop on Trachoma, Seattle, Washington, 1988

NIH Workshop on Microbial Determinants of Virulence and Host Response, Gainesville, Florida, 1989

Montana State University, Department of Microbiology, Bozeman, Montana, 1989

The Edna McConnell Clark Foundation: Trachoma Task Force Meeting, Easton, Maryland, 1989

University of Texas Health Science Center at San Antonio, Department of Microbiology, San Antonio, Texas, 1990

Co-Chairman, Immunobiology of Chlamydial Infection, Seventh International Symposium on Human Chlamydial Infection, Harrison Hot Springs, British Columbia, Canada, 1990

University of Wisconsin, Department of Medical Microbiology and Immunology, Madison, Wisconsin, 1990

ICAAC Symposia: Bacterial STD's - Structure and Immunology, Anaheim, California, 1992

University of Texas Health Science Center at San Antonio, Department of Microbiology, San Antonio, Texas, 1993

University of Indiana School of Medicine, Department of Microbiology and Immunology, Indianapolis, Indiana, 1993

South Dakota State University, Dept. of Biol. and Microbiol., Brookings, South Dakota, 1993

University of Alabama at Birmingham, Div. of Infectious Diseases, Birmingham, Alabama, 1993

New York Hospital - Cornell Medical Center, Department of Obstetrics and Gynecology, New York, New York. Medical Grand Rounds, 1995

University of Kansas, Dept. of Medicine, Kansas City, Kansas. Medical Grand Rounds, 1995

University of Kansas, Department of Microbiology, Kansas City, Kansas, 1995

Keystone Symposium: “*Chlamydia trachomatis* Genital Tract Infection in Gene Knockout Mice,” STDs in the HIV Era. Keystone, Colorado, Invited Speaker, 1995

Infectious Diseases Society for Obstetrics and Gynecology: “Immune Response to Chlamydial Genital Tract Infection”, Traverse City, Michigan, Invited Speaker, 1995

Infectious Diseases Society for Obstetrics and Gynecology: “Persistent Chlamydiae: from Cell Culture to a Paradigm for Chlamydial Pathogenesis”, Traverse City, Michigan, Presidential Guest Lecturer, 1995

University of Indiana, School of Medicine, Department of Microbiology and Immunology, Indianapolis, Indiana. Microbiology/Immunology Invited Speaker, 1996

University of Indiana, School of Medicine, Division of Infectious Diseases, Indianapolis, Indiana. Infectious Diseases Research Conference Invited Speaker, 1996

International Symposium on Immunopathogenesis of *Chlamydia* Infections, “Immune Protection against *C. trachomatis* in Females,” Cornell University Med. College, New York City, New York, Plenary Speaker, 1996.

SmithKline Beecham Biologics, Rixensart, Belgium. Invited Speaker, 1997.

Montana State University, Dept. Veterinary and Molecular Biology, Fall 1998

National Institute of Allergy and Infectious Disease, NIH, Rocky Mountain Laboratories: "Immunity to murine *Chlamydia trachomatis* genital tract infection: a paradigm revisited". Invited Speaker. February 2001.

University of Alabama-Birmingham School of Medicine, Division of Infection Diseases, Birmingham, AL. Infectious Disease Grand Rounds. “Immunity to Murine *Chlamydia trachomatis* Genital tract Infection”. Invited Speaker. November 2001.

University of Oklahoma Health Sciences Center, Department of Microbiology and Immunology, “Immunity to Chlamydial Genital Tract Infection”, Invited Speaker, February 2002

University of Oklahoma Health Sciences Center, Department of Microbiology and Immunology, invited lecturer for graduate student infectious disease course. Lecture: Chlamydiaceae; February 2002

Corixa, Seattle, WA. Lecture: “Pathogenesis of *Chlamydia trachomatis* genital tract infection. Feb. 2003.

Chlamydia Basic Research Society, Biennial Meeting, Memphis, TN; Immunology Panel Discussion, Co-Facilitator. March 2003.

Ligocyte, Bozeman, MT. Invited Speaker. Pathogenesis of genital and respiratory chlamydial infections. May 2003.

Sabin Vaccine Institute, Colloquium on Chlamydia Vaccine Development. Alexandria, VA. Lecture: “Current Knowledge of Chlamydial Immunity”. June 3-5, 2003.

Sabin Vaccine Institute, Colloquium on Chlamydia Vaccine Development. Alexandria, VA. Lecture: "Overview of Vaccine Development Investigations". June 3-5, 2003.

Dept. of Microbiology, University of Texas San Antonio, San Antonio, TX. Invited Speaker. "Immunity to Chlamydial Genital Tract Infection". April 14, 2005.

Chlamydia Basic Research Society, Biennial Meeting, Indianapolis, IN. "Antibody mediated resolution of chlamydial genital tract reinfection". April 23-25, 2005

Chlamydia Basic Research Society, Biennial Meeting, Indianapolis, IN. Immunology Panel Discussion: Facilitator. April 23-25, 2005

Chlamydial Vaccine Workshop, NIH, NIAID, Rocky Mountain Labs, Hamilton, MT. Invited speaker. "Murine model of chlamydial genital tract infection". August 23-24, 2005.

Chlamydial Vaccine Workshop, NIH, NIAID, Rocky Mountain Labs, Hamilton, MT. Invited speaker. "Role of antibody in immunity to chlamydial genital tract reinfection". August 23-24, 2005.

Trachoma Scientific Exchange Meeting, Phoenix, AZ. Invited speaker. "Protective immune correlates in murine chlamydial genital infection". January 27-30, 2006.

Infectious Disease Society of America, Toronto, Canada. Invited symposium speaker. "Insights into *C. trachomatis* host response: Human and animal studies and their implication for vaccine research". October 14, 2006.

Eleventh International Symposium on Human Chlamydial Infections, Niagara-on-the-Lake, Ontario, Canada. 'Humoral immunity to Chlamydia muridarum genital tract infection', June 18-23, 2006.

North Carolina State University, Raleigh, NC. Invited speaker. Immunity to Chlamydial Genital Tract Reinfection. March 2007

University of Arkansas for Medical Sciences. Little Rock, AR. Invited Speaker. Immunity to Chlamydial Genital Tract Reinfection. March 2007

University of Miami Miller School of Medicine, Department of Microbiology and Immunology, Miami, FL. Invited speaker. Immunity to Chlamydial Genital Infection: the shifting paradigm. April 2008

University of Texas San Antonio, South Texas Center for Emerging Infectious Diseases, San Antonio, TX. Invited speaker. Immunity to Chlamydial Genital Infection: the shifting paradigm. April 2008.

Chlamydia Basic Research Society, Biennial Meeting, Little Rock, AR. "Murine genital infection with human *Chlamydia trachomatis* serovars resolves in the absence of adaptive (CD4⁺ T cell) immune responses". March 20-23, 2009.

University of California Davis, Department of Microbiology and immunology. Invited Speaker. Immunity to Chlamydia genital infection. September 24-26, 2012

NIH, NIAID, Twinbrook, MD. Invited participant. Chlamydia Vaccines: the Way Forward, May 27-28, 2015

University of South Dakota, Division of Basic Sciences. Invited Speaker. Immune Responses that Protect Against Sexually Transmitted Chlamydia Infection: Implications for Vaccine Design. September 29, 2015.

GRANT SUPPORT (CURRENT)

Genetic Analysis of Mechanisms of Chlamydial Immune Evasion
2R56AI099278-06
NIH, NIAID
David Nelson (PI)

Richard P. Morrison, Ph.D. – Co-PI/PI on Subaward
05/01/2017 – 04/30/2018 \$415,735 (direct costs)

Microbial Pathogenesis and Host Inflammatory Responses (COBRE Phase II)
P20 GM103625-06
NIH, NIGMS
Mark Smeltzer (PI)

Richard P. Morrison, Ph.D. – Co-PI (Director Core B; Associate Director Core A)
5/01/2017 – 4/30/2022; \$7,500,000 (direct costs)

GRANT SUPPORT (PAST)

Microbial Pathogenesis and Host Inflammatory Responses (COBRE Phase I)
P20 GM103625-01
NIH, NIGMS
Mark Smeltzer (PI)

Richard P. Morrison, Ph.D. – Co-PI (Director Core B; Associate Director Core A)
8/15/2012 – 4/30/2017; \$7,400,000 (direct costs)

Genetic Analysis of Mechanisms of Chlamydial Immune Evasion
R01-AI099278-05
NIH, NIAID
David Nelson (PI)

Richard P. Morrison, Ph.D. – Co-PI/PI on Subaward
2/1/2012 – 1/31/2017; \$1,836,000 (direct costs)

Immunity to Chlamydial Genital Tract Infection
R01-AI38991 (yrs 10-14)
NIH, NIAID

Richard P. Morrison, Ph.D. - Principal Investigator
9/1/05 - 8/31/10; \$1,250,000 (direct costs)

Seroprevalence of *Chlamydia trachomatis* in Healthy Young Women.
Sanofi-Pasteur

Rciahrd P. Morrison, Ph.D. – Principal Investigator
2/1/2009 – 7/31/2010; \$100,641 (direct costs)

Chlamydia Pathogenesis
UAMS ABI

Richard P. Morrison, Ph.D. – Principal Investigator

7/1/07-6/30/09 \$300,000

Chlamydial Immunity

Department of Medicine Scholars of Excellence

Richard P. Morrison, Ph.D. – Principal Investigator

08/01/2004 – 07/31/2007; \$300,000 (direct costs)

Chlamydial Pathogenesis

Heath Service Foundation-General Endowment Fund Scholar Award

Richard P. Morrison, Ph.D. – Principal Investigator

09/01/2004 – 8/31/2006; \$100,000 (direct costs)

Immunity to Chlamydial Genital Tract Infection

R01-AI38991 (yrs 5-9)

NIH, NIAID

Richard P. Morrison, Ph.D. - Principal Investigator

9/30/00 - 10/1/05; \$1,000,000 (direct costs)

Medical Mycology Predoctoral Training Program

T32 AI07465

NIH, NIAID

Richard P. Morrison, Ph.D. – Program Director

09/01/2002 – 08/31/2004; \$116,452 (direct costs)

Immunity to *Chlamydia pneumoniae* Respiratory Infection

American Heart Association/National

Richard P. Morrison, Ph.D. - Principal Investigator

1/1/01 - 12/31/03; \$195,000 (direct costs)

Immunity to *Chlamydia pneumoniae* Infection

Grant-in-Aid #9951088Z

American Heart Association/N.W. Affiliate

Richard P. Morrison, Ph.D. - Principal Investigator

7/1/99 - 6/30/01; \$100,000 (direct cost)

Immunity to Chlamydial Genital Infection

RO1-AI38991-01/04

NIH, NIAID

Richard P. Morrison, Ph.D. - Principal Investigator

6/96 - 5/00; \$589,700 (direct cost)

Identification of T-cell Epitopes on *C. trachomatis* MOMP

The Edna McConnell Clark Foundation

Richard P. Morrison, Ph.D. - Principal Investigator

Grant #14088; 10/88 - 9/90; \$226,624 (direct costs)

Protective and Deleterious Immune Responses in Guinea Pig Inclusion Conjunctivitis

The Edna McConnell Clark Foundation

Richard P. Morrison, Ph.D. - Principal Investigator

Grant #12186; 10/86 - 9/88; \$125,109 (direct costs)

OTHER:

Patents:

Morrison RP and Caldwell HD. US Patent 5,071,962

Morrison RP and Caldwell HD. US Patent 6,423,835

BIBLIOGRAPHY

Manuscripts

1. **Morrison RP**, and Cutler JE. *In vitro* studies of the interactions of murine phagocytic cells in *Candida albicans*. J Reticuloendothel Soc 1981;29:23-34.
2. **Morrison RP**, Nishio J, and Chesebro B. Influence of the murine major histocompatibility complex (H-2) on Friend leukemia virus-induced immunosuppression. J Exp Med 1986;163:301-314.
3. Earl PL, Moss B, **Morrison RP**, Wehrly K, Nishio J, and Chesebro B. T lymphocyte priming and protection against Friend leukemia by a vaccinia-retrovirus env gene recombinant. Science 1986;234:728-731.
4. **Morrison RP**, Earl PL, Nishio J, Lodnell DL, Moss B, and Chesebro B. Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature 1987;329:729-732.
5. **Morrison RP**, Lyng K, and Caldwell HD. Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein. J Exp Med 1989;169:663-675.
6. **Morrison RP**, Belland RJ, Lyng K, and Caldwell HD. Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. J. Exp Med. 1989;170:1271-1283.
7. **Morrison RP**, Su H, Lyng K, and Yuan Y. *Chlamydia trachomatis hyp* operon is homologous to the *groE* stress response operon of *Escherichia coli*. Infect Immun 1990;58:2701-2705.
8. Su H, **Morrison RP**, Watkins NG, and Caldwell HD. Identification and characterization of T helper-cell epitopes of the major outer membrane protein of *Chlamydia trachomatis*. J Exp Med 1990;172:203-212.
9. Evans LH, **Morrison RP**, Malik FG, Portis J, and Britt WJ. A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic and amphotropic murine leukemia viruses. J Virol 1990;64:6176-6183.
10. **Morrison RP**. Chlamydia hsp60 and the immunopathogenesis of chlamydial disease. Seminars in Immunology 1991;3:25-33.
11. Yuan Y, Lyng K, Zhang Y-X, Rockey DD, and **Morrison RP**. Monoclonal antibodies define genus-specific, species-specific, and cross-reactive epitopes of the chlamydial 60 kilodalton heat shock protein (hsp60): specific immunodetection and purification of chlamydial hsp60. Infect Immun 1992;60:2288-2296.

12. Beatty WL, Byrne GI, and **Morrison RP**. Morphologic and antigenic characterization of interferon- γ mediated persistent *Chlamydia trachomatis* infection *in vitro*. Proc Natl Acad Sci USA 1993;90:3998-4002.
13. Byrne GI, Stephens RS, Ada G, Caldwell HD, Su H, **Morrison RP**, Van der Pol B, et al. Workshop on the *in vitro* neutralization of *Chlamydia trachomatis*: Summary of proceedings. J Infect Dis 1993;168:415-420.
14. Beatty WL, Belinger TA, Le KD, Desai AA, **Morrison RP**, and Byrne GI. Chlamydial persistence: mechanism of induction and parallels to a stress related response. In Orfila J, Byrne GI, Chernesky MA, Grayston JT, Jones RB, Ridgway GL, Saikku P, Schachter J, Stamm WE, and Stephens RS (Eds): Chlamydial infections. Societa Editrice Esculapio, Bologna, Italy. 1994, pp 415-418.
15. Beatty WL, Byrne GI, and **Morrison RP**. Repeated and persistent infection with *Chlamydia* and the development of chronic inflammation and disease. Trends in Microbiology 1994;2:94-98.
16. Beatty WL, Belanger TA, Desal AA, **Morrison RP**, and Byrne GI. Role of tryptophan in gamma-interferon mediated chlamydial persistence. New York Acad Sci 1994; 730: 304-306.
17. Beatty WL, Belinger TA, Desal AA, **Morrison RP**, and Byrne GI. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994; 62: 3705-3711.
18. Beatty WL, **Morrison RP**, and Byrne GI. Immuno electron-microscopic quantitation of different levels of chlamydial proteins in a cell culture model of persistent *Chlamydia trachomatis* infection. Infect. Immun. 1994; 62: 4059-4062.
19. Beatty WL, **Morrison RP**, and Byrne GI. Persistent *Chlamydia*: from cell culture to a paradigm for chlamydial pathogenesis. Microbiological Rev. 1994; 58:686-699.
20. Beatty WL, **Morrison RP**, and Byrne GI. Reactivation of persistent *Chlamydia trachomatis* infection in cell culture. Infect. Immun. 1995;63:199-205.
21. Rosenberg HF, **Morrison RP**, and Li F. Identification of a 40-kDa human protein that cross-reacts with prokaryotic HSP60/chaperonins. Biochem. Biophys. Res. Commun. 1995;208:697-703.
22. Arno JN, Yuan Y, Cleary RE and **Morrison RP**. Serologic response of infertile women to the 60-kd chlamydial heat shock protein (hsp60). Fertility Sterility. 1995;64:730-735.
23. **Morrison RP**, Feilzer K, and Tumas DB. Gene knockout mice establish a primary protective role for MHC class II-restricted responses in *Chlamydia trachomatis* genital tract infection. Infect. Immun. 1995;63:4661-4668.
24. **Morrison, RP**. Immune protection against *Chlamydia trachomatis* in females. Infect. Dis. Obstet. Gynecol. 1996;4:163-170.
25. Su H, Feilzer K, Caldwell HD, and **Morrison RP**. *Chlamydia trachomatis* genital tract infection of antibody- deficient gene knockout mice. Infect. Immun. 1997;65:1993-1999.

26. **Morrison RP.** Persistent *Chlamydia trachomatis* infection: an in vitro phenomenon or an in vivo trigger of reactive arthritis. *J. Rheumatol.* 1998;25:610-612.
27. Han Y, **Morrison RP**, and Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to *Candida albicans* vaginal infection. *Infect. Immun.* 1998;66:5771-5776.
28. Kalayoglu M, Hoerneman B, LaVerda D, Morrison SG, **Morrison RP**, Byrne GI. Cellular oxidation of low density lipoprotein by *Chlamydia pneumoniae*. *J. Infect. Dis.* 1999; 180:780-790.
29. Su H, **Morrison R**, Messer R, Whitmire W, Hughes S, and Caldwell HD. The effect of antibiotic intervention on the development of protective immunity against chlamydial genital infection. *J. Infect. Dis.* 1999;180:1252-1258.
30. LaVerda D, Albanese LN, Ruther P, Morrison SG, **Morrison RP**, Ault KA, and Byrne GI. Seroreactivity to *Chlamydia trachomatis* hsp10 correlates with disease severity in women. *Infect. Immun.* 2000;68:303-309.
31. Mosorin M, Surcel H-M, Laurila A, Lehtinen M, Karttunen R, Juvonen J, Paavonen J, **Morrison RP**, Saikku P, and Juvonen T. Detection of *Chlamydia pneumoniae* reactive T lymphocytes in human atherosclerotic plaques of carotid artery. *Arterioscler. Thrombo. Vasc. Biol.* 2000; 20:1061-1067
32. Morrison SG and **Morrison RP.** In situ analysis of the evolution of the primary immune response in murine *Chlamydia trachomatis* genital tract infection. *Infect. Immun.* 2000;68:2870-2879.
33. Kalayoglu MV, Indrawati, **Morrison RP**, Morrison SG, Yuan Y, Byrne GI. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. *J. Infect. Dis.* 2000; 181(Suppl 3):S483-S489.
34. Kinnunen A, Molander P, Laurila A, Rantala I, **Morrison R**, Lehtinen M, Karttunen R, Paavonen J, and Surcel H-M. *Chlamydia trachomatis* reactive T lymphocytes from upper genital tract tissue specimens. *Hum. Reprod.* 2000; 15:1484-1489.
35. **Morrison RP.** Differential sensitivity of *Chlamydia trachomatis* strains to the inhibitory effects of gamma interferon. *Infect. Immun.* 2000; 68:6038-6040.
36. Morrison SG, Su H, Caldwell HD, **Morrison RP.** Immunity to murine *Chlamydia trachomatis* genital tract reinfection involves B cells and CD4+ T cells but not CD8+ T cells. *Infect. Immun.* 2000; 68:6979-6987.
37. Morrison SG and **Morrison RP.** Resolution of secondary *Chlamydia trachomatis* genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. *Infect. Immun.* 2001; 69:2643-2649.
38. Kinnunen A, Molander P, **Morrison R**, Lehtinen M, Karttunen R, Tiitinen A, Paavonen J, and Surcel H-M. Chlamydial heat shock protein 60-specific T cells in inflamed salpingeal tissue. *Fertil. Steril.* 2002; 77:162-166.

39. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, Morrison SG, **Morrison RP**, and Arditi M. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor-4 and MD2 in a MyD88-dependent pathway. *J. Immunol.* 2002; 168:1435-1440.
40. **Morrison RP** and Caldwell HD. Mini Review. Immunity to murine chlamydial genital infection. *Infect. Immun.* 2002; 70:2741-2751.
41. Kinnunen A, Surcel H-M, Lehtinen M, Karhukorpi J, Tiitinen A, Halttunen M, Bloigu A, Kivela H, **Morrison RP**, Karttunen R, and Paavonen J. HLA DQ alleles and interleukin-10 polymorphism associated with *Chlamydia trachomatis*-related tubal factor infertility: a case-control study. *Hum. Reprod.* 2002; 17:2073-2078.
42. Kinnunen A, Surcel H-M, Halttunen M, Tiitinen A, **Morrison RP**, Morrison SG, Koskela P, Lehtinen M, and Paavonen J. *Chlamydia trachomatis* heat shock protein-60 induced interferon- γ and interleukin-10 production in infertile women. *Clin. Exp. Immunol.* 2003; 131:299-303.
43. Jacobs JM, Bailey BW, Burritt JB, Morrison SG, **Morrison RP**, Dratz EA, Jesaitis AJ, and Teintze M. QSYP peptide sequence is selected from phage display libraries by bovine IgG contaminants in monoclonal antibody preparations. *Biotechniques* 2003; 34:132-141.
44. **Morrison RP**. New insights into a persistent problem – chlamydial infections. *J. Clin. Invest.* 2003; 111:1647-1649.
45. Perschinka H, Mayr M, Millonig G, Mayerl C, van der Zee R, Morrison SG, **Morrison RP**, Xu Q, and Wick G. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 2003; 23:1060-1065.
46. Morrison SG and **Morrison RP**. The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of IgA. *Infect. Immun.* 2005; 73:6183-6186.
47. Morrison SG and **Morrison RP**. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. *J. Immunol.* 2005; 175:7536-7542.
48. Morrison SG and **Morrison RP**. Humoral immunity to *Chlamydia muridarum* genital tract reinfection. *Chlamydial Infections: Proceedings of the Eleventh International Symposium on Human Chlamydial Infections.* 2006; 373-376.
49. Tiitinen A, Surcel H-M, Halttunen M, Birkelund S, Bloigu A, Christiansen G, Koskela P, Morrison SG, **Morrison RP**, and Paavonen J. *Chlamydia trachomatis* and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility. *Hum. Reprod.* 2006; 21:1533-1538.
50. Farris CM, Morrison SG and **Morrison RP**. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to *Chlamydia muridarum* genital infection. *Infect. Immun.* 2010; 78:4374-4383.
51. Farris CM and **Morrison RP**. Vaccination against chlamydial genital infection utilizing the murine *C. muridarum* model. *Infect. Immun.* 2011; 79:986-996.

52. Morrison SG, Farris CM, Sturdevant GL, Whitmire WM and **Morrison RP**. Murine *Chlamydia trachomatis* genital infection is unaltered by depletion of CD4⁺ T cells and diminished adaptive immunity. *J. Infect. Dis.* 2011; 203:1120-1128.
53. Geisler WM, Morrison SG, Doemland M, Iqbal S, Su J, Mancevski A, Hook III EW, **Morrison RP**. Immunoglobulin-specific responses to *Chlamydia* elementary bodies in individuals with and at risk for genital chlamydial infection. *J. Infect. Dis.* 2012; 206:1836-1843.
54. Rajaram K, Giebel AM, Toh E, Hu S, Newman JH, Morrison SG, Kari L, **Morrison RP**, and Nelson DE. Mutational analysis of the *Chlamydia muridarum* plasticity zone. *Infect. Immun.* 2015; 83:2870-2881.
55. Naglak EK, Morrison SG, and **Morrison RP**. Gamma Interferon is required for optimal antibody-mediated immunity against genital *Chlamydia* infection. *Infect. Immun.* 2016; 84:3232-3242.
56. Bakshi R, Gupta K, Jordan SJ, Brown L, Press CG, Gorwitz R, Papp J, Morrison SG, Lee JY, **Morrison RP**, and Geisler WM. Immunoglobulin-Based Investigation of Spontaneous Resolution of *Chlamydia trachomatis* Infection. *J. Infect. Dis.* 2017; 215:1653-1656.
57. Naglak, EK, Morrison SG and **Morrison RP**. Neutrophils are Central to Antibody-Mediated Protection against Genital Chlamydia. *Infect. Immun.* 2017; in press.

Manuscripts Submitted:

Wang L, Zhu C, Zhang T, Tian Q, Zhang N, Morrison SG, **Morrison RP**, Xue M, and Zhong G. Non-pathogenic colonization with *Chlamydia muridarum* in the gastrointestinal tract as oral vaccination for inducing transmucosal protection.

Manuscripts In Preparation:

Giebel AM, Hu S, Rajaram K, Finethy R, Toh E, Brothwel JA, **Morrison RP**, Morrison SG, Suchland RJ, Stein BD, Coers J, and Nelson DE. Inhibition of apoptotic host cell killing is critical for *Chlamydia* interferon evasion.

Morrison SG, Giebel AM, Toh E, Nelson DE, and **Morrison RP**. A *Chlamydia muridarum* mutant exhibiting remarkable tissue-specific virulence.

Books and Book Chapters

1. **Morrison RP**, Nishio J, and Chesebro B. Immunosuppression induced by the Friend murine leukemia virus complex in mice with Rfv-3^{r/s} genotype. In Salzman LA (Ed.): *Animal Models of Retrovirus infection and Their Relationship to AIDS*, Orlando, FL, Academic Press, 1986, pp. 279-284.
2. **Morrison RP**, Chesebro B, Nishio J, Wehrly K, Earl P, and Moss B. Induction of primed T lymphocytes and protection against Friend murine leukemia by recombinant vaccinia virus expressing the Friend retrovirus envelope gene. In Chanock RM, Lerner RA, Brown F, and Ginsberg H (Eds.): *Vaccines 87: Modern Approaches to New Vaccines*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1987, pp. 268-272.

3. **Morrison RP.** Chlamydial 57-kilodalton stress response protein is a deleterious immune target. In Ayoub EM, Cassell GH, Branche WC, Jr., and Henry TJ (Eds.): *Microbial Determinants of Virulence and Host Response*, Washington, DC, American Society for Microbiology, 1990, pp. 243-250.
4. **Morrison RP.** Immune responses to *Chlamydia* are protective in pathogenesis. In Bowie WR, Caldwell HD, Jones RP, Mardh PA, Ridgway GL, Schachter J, Stamm, WE and Ward ME (Eds.): *International Symposium on Human Chlamydial Infections*, Cambridge, Cambridge University Press, 1990, pp. 163-172.
5. **Morrison RP**, Manning DS, and Caldwell HD. Immunology of *Chlamydia trachomatis* infections: Immunoprotective and immunopathogenic responses. In Gallin JI, and Fauci AS (Eds.): *Advances in Host Defense Mechanisms*, Raven Press, 1992, vol. 8, pp. 57-84.
6. **Morrison RP** and Rank RG. Chlamydial Sequelae: Mechanisms of Immune Damage in Trachoma and Genital Tract Infections. In Cunningham MW and Fujinami RS, Editors: *Effects of Microbes on the Immune System*, Lippincott-Raven Publishers, 2000, pp. 41-55.
7. **Morrison RP.** Chlamydial Immunology and Vaccinology. *Proceedings of the Chlamydial Vaccine Development Colloquium*. 2003. pp. 19-22.
8. Russell MW, Sparling PF, **Morrison RP**, Cauci S, Fidel, Jr PL, Martin D, Hook III EW, Mestecky J. Mucosal immunology of sexually transmitted diseases. In Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L. Editors: *Mucosal Immunology*, Academic Press/Elsevier, 2005, pp.1693-1720.

Chapter: In Preparation

Lee, D. **Morrison, R.P.** and Darville, T. Mucosal Vaccines for Bacterial Sexually Transmitted Diseases. *In: Mucosal Vaccines: Innovation for Preventing Infectious Diseases*, Edited by Hirisho Kiyono & David Pascual. Elsevier Publishers.